Tecentriq (atezolizumab) - Roche
Tecentriq: Regulatory submissions in Japan for ovarian cancer, muscle-invasive urothelial cancer (adjuvant) and hepatocellular cancer in 2020 (Chugai) - Oct 25, 2019 - Q3 2019 Results: Regulatory submissions in Japan for early breast cancer and NSCLC (neoadjuvant) in 2021 
Japanese regulatory
https://www.chugai-pharm.co.jp/english/ir/reports_downloads/presentations.html#sec_84
 
Oct 25, 2019
 
 
d13fded8-8c13-4f55-8fd1-d4fd42fa9776.jpg